Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been
substantially improved with the emergence of novel therapeutic agents, such as proteasome …

CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively
low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic …

The myeloma surface proteome (surfaceome) determines tumor interaction with the
microenvironment and serves as an emerging arena for therapeutic development. Here, we …

MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

The anti-CD38 monoclonal antibody daratumumab is well tolerated and has high single
agent activity in heavily pretreated relapsed and refractory multiple myeloma (MM) …

CD 38 is a multifunctional cell surface protein that has receptor as well as enzyme functions.
The protein is generally expressed at low levels on various hematological and solid tissues …

Purpose: Knowledge about the mechanism of action (MoA) of monoclonal antibodies (mAb)
is required to understand which patients with multiple myeloma (MM) benefit the most from a …

CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of
migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed …